Loprox
(ciclopirox)PreclinicalSmall molecule
Loprox is one of 39 small molecule programs targeting Prevention. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
38
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Prevention
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Prograf
VVeloxis Pharmaceuticals
Phase 3
Prolia
OOrganon and Co
Phase 3
Fludara
SanofiPhase 2
Nolvadex
AstraZenecaPhase 2
Orencia
Bristol-Myers SquibbPhase 2
Yescarta
GileadPhase 2
Ilaris
NovartisPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
BCG Vaccine
GGynecologic Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 30, 1982
LOPROX
NDA NDA018748
Dec 30, 1988
LOPROX
NDA NDA019824
Jul 21, 1997
CICLOPIROX
NDA NDA020519
Dec 17, 1999
PENLAC
NDA NDA021022
Feb 28, 2003
LOPROX
NDA NDA021159
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ciclopirox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- EEurofarma Laboratorios S.A.